Dr Reddy's Labs launches Ziprasidone Mesylate for injection in US market
Business

Dr Reddy's Labs launches Ziprasidone Mesylate for injection in US market

Agency News

Hyderabad, Mar 17 : Dr Reddy’s Laboratories Limited on Tuesday announced the launch of Ziprasidone Mesylate for Injection, 20 mg (base)/mL single-dose Vials, the therapeutic generic equivalent of Geodon (Ziprasidone Mesylate) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration (USFDA). “We’re pleased to bring the first generic of Ziprasidone Mesylate for Injection to market for patients who will benefit from access to affordable medicine.

With every new product launch, we believe we are making healthcare more affordable by delivering value to the pharmacy,” Mr Marc Kikuchi, Chief Executive Officer, North America Generics, Dr Reddy’s Laboratories said.

“This is a great addition to our injectable offering in the U.S. market as we continue to augment our portfolio and drive growth within the hospital segment,” he added. The Geodon brand had US sales of approximately USD 21.8 million MAT for the most recent 12 months ending in January 2020 according to IQVIA Health, a company statement here said. (UNI)

pennews
www.pennews.net